|
|||||
|
|
Intracoronary allogeneic cardiosphere‐derived stem cells are safe for use in dogs with dilated cardiomyopathy |
|
| Authors: | Kathleen Woodruff Teresa Defrancesco Sandra Tou Christina M. Williams Mathew Breen Kathryn Meurs Bruce Keene Ke Cheng |
| Affiliation: | 1. Department of Clinical Sciences, North Carolina State University, Raleigh, NC, USA;2. Department of Molecular Biomedical Sciences and Comparative Medicine Institute, North Carolina State University, Raleigh, NC, USA;3. Center for Human Health and the Environment, North Carolina State University, Raleigh, NC, USA;4. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA;5. Joint Department of Biomedical Engineering, University of North Carolina Chapel Hill and North Carolina State University, Raleigh and Chapel Hill, NC, USA;6. Eshelman School of Pharmacy, University of North Carolina Chapel Hill, Chapel Hill, NC, USA |
| Abstract: | Cardiosphere‐derived cells (CDCs) have been shown to reduce scar size and increase viable myocardium in human patients with mild/moderate myocardial infarction. Studies in rodent models suggest that CDC therapy may confer therapeutic benefits in patients with non‐ischaemic dilated cardiomyopathy (DCM). We sought to determine the safety and efficacy of allogeneic CDC in a large animal (canine) model of spontaneous DCM. Canine CDCs (cCDCs) were grown from a donor dog heart. Similar to human CDCs, cCDCs express CD105 and are slightly positive for c‐kit and CD90. Thirty million of allogeneic cCDCs was infused into the coronary vessels of Doberman pinscher dogs with spontaneous DCM. Adverse events were closely monitored, and cardiac functions were measured by echocardiography. No adverse events occurred during and after cell infusion. Histology on dog hearts (after natural death) revealed no sign of immune rejection from the transplanted cells. |
| Keywords: | cardiosphere‐derived cells dogs dilated cardiomyopathy stem cell therapy allogeneic |